FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3096550948> ?p ?o ?g. }

• W3096550948 endingPage "260" @default.
• W3096550948 startingPage "249" @default.
• W3096550948 abstract "Diffuse large B-cell lymphoma (DLBCL) is the major type of aggressive B-cell lymphoma. High-grade B-cell lymphoma (HGBCL) with MYC/BCL2 double-hit (DH) represents a distinct entity with dismal prognosis after standard immunochemotherapy in the current WHO lymphoma classification. However, whether TP53 mutation synergizes with MYC abnormalities (MYC rearrangement and/or Myc protein overexpression) contributing to HGBCL-like biology and prognosis is not well investigated. In this study, patients with DLBCL with MYC/TP53 abnormalities demonstrated poor clinical outcome, high-grade morphology, and distinct gene expression signatures. To identify more effective therapies for this distinctive DLBCL subset, novel MYC/TP53/BCL-2-targeted agents were investigated in DLBCL cells with MYC/TP53 dual alterations or HGBCL-MYC/BCL2-DH. A BET inhibitor INCB057643 effectively inhibited cell viability and induced apoptosis in DLBCL/HGBCL cells regardless of MYC/BCL2/TP53 status. Combining INCB057643 with a MDM2-p53 inhibitor DS3032b significantly enhanced the cytotoxic effects in HGBCL-DH without TP53 mutation, while combining with the BCL-2 inhibitor venetoclax displayed potent therapeutic synergy in DLBCL/HGBCL cells with and without concurrent TP53 mutation. Reverse-phase protein arrays revealed the synergistic molecular actions by INCB057643, DS3032b and venetoclax to induce cell-cycle arrest and apoptosis and to inhibit AKT/MEK/ERK/mTOR pathways, as well as potential drug resistance mechanisms mediated by upregulation of Mcl-1 and RAS/RAF/MEK/ERK pathways. In summary, these findings support subclassification of DLBCL/HGBCL with dual MYC/TP53 alterations, which demonstrates distinct pathobiologic features and dismal survival with standard therapy, therefore requiring additional targeted therapies. IMPLICATIONS: The clinical and pharmacologic studies suggest recognizing DLBCL with concomitant TP53 mutation and MYC abnormalities as a distinctive entity necessary for precision oncology practice. VISUAL OVERVIEW: http://mcr.aacrjournals.org/content/molcanres/19/2/249/F1.large.jpg." @default.
• W3096550948 created "2020-11-09" @default.
• W3096550948 creator A5003670546 @default.
• W3096550948 creator A5008975834 @default.
• W3096550948 creator A5010675319 @default.
• W3096550948 creator A5013543100 @default.
• W3096550948 creator A5014966517 @default.
• W3096550948 creator A5016540674 @default.
• W3096550948 creator A5016760892 @default.
• W3096550948 creator A5019290469 @default.
• W3096550948 creator A5020930480 @default.
• W3096550948 creator A5022581561 @default.
• W3096550948 creator A5023214008 @default.
• W3096550948 creator A5027080346 @default.
• W3096550948 creator A5032347848 @default.
• W3096550948 creator A5041171016 @default.
• W3096550948 creator A5041326568 @default.
• W3096550948 creator A5057884333 @default.
• W3096550948 creator A5058183790 @default.
• W3096550948 creator A5058982057 @default.
• W3096550948 creator A5063684236 @default.
• W3096550948 creator A5064786948 @default.
• W3096550948 creator A5065256751 @default.
• W3096550948 creator A5069484088 @default.
• W3096550948 creator A5073976864 @default.
• W3096550948 creator A5077005650 @default.
• W3096550948 creator A5085410438 @default.
• W3096550948 creator A5086966125 @default.
• W3096550948 creator A5089689144 @default.
• W3096550948 date "2021-02-01" @default.
• W3096550948 modified "2023-10-18" @default.
• W3096550948 title "Aggressive B-cell Lymphoma with MYC/TP53 Dual Alterations Displays Distinct Clinicopathobiological Features and Response to Novel Targeted Agents" @default.
• W3096550948 cites W1509245076 @default.
• W3096550948 cites W1549574050 @default.
• W3096550948 cites W1968117566 @default.
• W3096550948 cites W1980577287 @default.
• W3096550948 cites W1988817337 @default.
• W3096550948 cites W2021536610 @default.
• W3096550948 cites W2022013393 @default.
• W3096550948 cites W2024972915 @default.
• W3096550948 cites W2028850684 @default.
• W3096550948 cites W2037904581 @default.
• W3096550948 cites W2056641238 @default.
• W3096550948 cites W2057239580 @default.
• W3096550948 cites W2059470125 @default.
• W3096550948 cites W2062831570 @default.
• W3096550948 cites W2068678285 @default.
• W3096550948 cites W2069813709 @default.
• W3096550948 cites W2078505025 @default.
• W3096550948 cites W2082534786 @default.
• W3096550948 cites W2096596684 @default.
• W3096550948 cites W2097202399 @default.
• W3096550948 cites W2120415962 @default.
• W3096550948 cites W2144311569 @default.
• W3096550948 cites W2162779900 @default.
• W3096550948 cites W2192121806 @default.
• W3096550948 cites W2201350031 @default.
• W3096550948 cites W2310716991 @default.
• W3096550948 cites W2529651453 @default.
• W3096550948 cites W2530587853 @default.
• W3096550948 cites W2532606512 @default.
• W3096550948 cites W2554298913 @default.
• W3096550948 cites W2582696216 @default.
• W3096550948 cites W2624307079 @default.
• W3096550948 cites W2625442338 @default.
• W3096550948 cites W2744261860 @default.
• W3096550948 cites W2745960854 @default.
• W3096550948 cites W2772062014 @default.
• W3096550948 cites W2777457443 @default.
• W3096550948 cites W2790840176 @default.
• W3096550948 cites W2792038348 @default.
• W3096550948 cites W2793399311 @default.
• W3096550948 cites W2797584152 @default.
• W3096550948 cites W2801763724 @default.
• W3096550948 cites W2891677691 @default.
• W3096550948 cites W2891731267 @default.
• W3096550948 cites W2922237910 @default.
• W3096550948 cites W2922501427 @default.
• W3096550948 cites W2952763999 @default.
• W3096550948 cites W2973850435 @default.
• W3096550948 cites W2983897734 @default.
• W3096550948 cites W3044002025 @default.
• W3096550948 doi "https://doi.org/10.1158/1541-7786.mcr-20-0466" @default.
• W3096550948 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/8092941" @default.
• W3096550948 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/33154093" @default.
• W3096550948 hasPublicationYear "2021" @default.
• W3096550948 type Work @default.
• W3096550948 sameAs 3096550948 @default.
• W3096550948 citedByCount "17" @default.
• W3096550948 countsByYear W30965509482021 @default.
• W3096550948 countsByYear W30965509482022 @default.
• W3096550948 countsByYear W30965509482023 @default.
• W3096550948 crossrefType "journal-article" @default.
• W3096550948 hasAuthorship W3096550948A5003670546 @default.
• W3096550948 hasAuthorship W3096550948A5008975834 @default.
• W3096550948 hasAuthorship W3096550948A5010675319 @default.
• W3096550948 hasAuthorship W3096550948A5013543100 @default.
• W3096550948 hasAuthorship W3096550948A5014966517 @default.

• next